BUY COINBASE: Davidson analyst Christopher Brendler assumed coverage of Coinbase ($COIN) with a Buy rating though with a lower price target of $400, down from $650. The analyst argued that blockchain technology is a "revolutionary innovation that will transform financial services," and while volatility remains high and use cases are still developing, he expects the recent events to ensure a "crypto future." Brendler added that Coinbase is very well positioned to capitalize on new opportunities including staking, lending, and DeFi. SUCCESS STORY: Evercore ISI analyst Omar Saad initiated coverage of Victoria's Secret ($VSCO) with an Outperform rating and $100 price target following its spinoff from L Brands. Victoria's Secret has been one of the most dramatic success stories from pre-COVID to today, with a much more modern, inclusive, and relevant brand message accompanied by a leaner business model, stronger pricing power, more disciplined inventory and promotions, and 1,000+ bps of margin expansion, Saad told investors in a research note. RISK/REWARD MORE ATTRACTIVE: Deutsche Bank analyst Brian Mullan upgraded Dine Brands ($DIN) to Buy from Hold with a price target of $93, down from $102, following the company's earnings report late last week. Amid a broader pullback in casual dining stocks, Dine is down about 27% from its high three months ago, making its risk/reward more attractive, Mullan told investors. He believes sustainable downside is "relatively limited from current levels" given his view that the business recovery is largely intact. MOVING TO THE SIDELINES: Goldman Sachs analyst Salveen Richter downgraded Bluebird Bio ($BLUE) to Neutral from Buy with a price target of $23, down from $63. Richter cited both the newly announced clinical hold for Lenti-D in cerebral adrenoleukodystrophy, or CALD, due to a Suspected Unexpected Serious Adverse Reaction of myelodysplastic syndrome in one patient, as well as the company's decision to wind down its operations in Europe and potentially license the rights outside the U.S. to its three lead gene therapy products in sickle cell disease, beta thalassemia and CALD, which "diminishes [Bluebird's] revenue opportunity given the major geography." Wells Fargo analyst Yanan Zhu also downgraded Bluebird Bio to Equal Weight from Overweight with a price target of $25, down from $60, following the update across the company's Lenti-D, LentiGlobin, and ABECMA programs that came along with the company's earnings report. Zhu's "main concern" is around the MDS case reported from the study of Lenti-D in CALD, and "more importantly" its potential implications for the company's LentiGlobin program in sickle cell disease, or SCD. The MDS observation made with Lenti-D could have potential implication for LentiGlobin in terms of regulatory hurdles and/or physician/patient adoption, contended Zhu, who would take a "wait-and-see approach."Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .